Skip to main content

Table 2 Demographic and clinical variables comparing control subjects with schizophrenia cases for the DAB immunohistochemical analysis

From: Increased levels of a pro-inflammatory IgG receptor in the midbrain of people with schizophrenia

Demographics

DAB immunohistochemistry cohort

Control

Schizophrenia

Statistics

n

28

30

Age (years)

52.5 (22–69)

54.5 (26–67)

t(56) = − 0.27, p = 0.78

Sex (M, F)

18,10

19,11

X2 = 0.006, p = 0.94

pH

6.6 ± 0.28 (5.8–7.0)

6.4 ± 0.23 (5.8–6.8)

t(56) = 2.56 p = 0.01**

PMI (h)

32.8 ± 9.7 (15–50)

36.2 ± 17.7 (5–72)

t(45.5) = − 0.90, p = 0.37

RIN

5.4 ± 1.2 (2.6–7.3)

5.4 ± 1.4 (2.7–8.3)

t(56) = 0.14, p = 0.98

Age at illness onset (years)

22.2 ± 7.2 (15–46)

Duration of illness (years)

29.6 ± 12.7 (4–49)

Daily CPZ equivalent dose (mg)a

736.5 ± 520.5 (200–2363)

Last recorded CPZ equivalent dose (mg)b

630.7 ± 520.3 (20–1732)

  1. Bold indicates statistical significance
  2. Age is written as median (range). All other values are written as mean ± standard deviation (range). M = male, F = female; RIN = RNA integrity number; PMI = post-mortem interval; CPZ = chlorpromazine. a schizophrenia cases n = 19. b schizophrenia cases n = 25